Tier 2 - plausible but unproven The evidence for cardiovascular and kidney benefits are one layer down
Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia
Almost certainly, yes, you will gain back some of the weight you lost
The downstream health savings from that magnitude of weight loss include: | Potential Savings | Annual Value | |-------------------|-------------| | Reduced diabetes risk/medications -- see [GLP-1 comparison chart](/guides/glp1-medications-comparison-chart-guide) for all options | $2,000-6,000 | | Blood pressure medication reduction | $600-1,800 | | Sleep apnea treatment reduction | $1,200-3,600 | | Avoided bariatric surgery | $20,000-35,000 (one-time) | | Reduced joint replacement risk | $30,000-50,000 (lifetime) | Against a first-year cost of $3,000-5,500 for compounded retatrutide, the financial case is strong for patients who respond well
469 Importantly, the GLP-1-carotid body pathway may represent a novel therapeutic target for managing cardiovascular metabolism and treating patients with diabetes and hypertension who exhibit heightened sympathetic activity
GLP-1R works through the combination of the endogenous ligand Glucagon-like peptide-1 (GLP-1) or exogenous agonists, which activate multiple intracellular signaling pathways that enhance insulin secretion, inhibit glucagon secretion, protect -cells from apoptosis, delay gastric emptying and increase satiety